{"protocolSection":{"identificationModule":{"nctId":"NCT05266105","orgStudyIdInfo":{"id":"OP-1250-002"},"organization":{"fullName":"Olema Pharmaceuticals, Inc.","class":"INDUSTRY"},"briefTitle":"A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients","officialTitle":"A Phase 1 Dose Escalation and Expansion Open-label, Multicenter, Study of OP-1250 in Combination With the CDK4/6 Inhibitor Palbociclib in Adult Subjects With Advanced or Metastatic HR-positive, HER2-negative Breast Cancer"},"statusModule":{"statusVerifiedDate":"2025-11","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-12-10","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-03","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-03","type":"ESTIMATED"},"studyFirstSubmitDate":"2022-02-11","studyFirstSubmitQcDate":"2022-02-23","studyFirstPostDateStruct":{"date":"2022-03-04","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-11-19","lastUpdatePostDateStruct":{"date":"2025-11-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Olema Pharmaceuticals, Inc.","class":"INDUSTRY"},"collaborators":[{"name":"Pfizer","class":"INDUSTRY"}]},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"This is an open-label, Phase 1b dose escalation and expansion study to determine the maximum tolerated dose (MTD) of OP-1250 in combination with palbociclib (Ibrance®️, Pfizer Inc.). Purpose of study is to evaluate the safety and pharmacokinetic (PK) profile, and estimate the preliminary anti-tumor activity of the combination in adult subjects with hormone receptor-positive (ER+ / HER2-) advanced or metastatic breast cancer (MBC)."},"conditionsModule":{"conditions":["Breast Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":60,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Dose Escalation","type":"EXPERIMENTAL","description":"This portion of the study will evaluate the safety and pharmacology of a range of OP-1250 doses administered daily with Palbociclib in subjects with advanced and/or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer","interventionNames":["Drug: Palazestrant","Drug: Palbociclib"]},{"label":"Dose Expansion","type":"EXPERIMENTAL","description":"This portion of the study further explores the clinical activity, safety and pharmacology of OP-1250 in combination with Palbociclib and estimates preliminary data of anti-tumor efficacy","interventionNames":["Drug: Palazestrant","Drug: Palbociclib"]}],"interventions":[{"type":"DRUG","name":"Palazestrant","description":"Complete Estrogen Receptor Antagonist","armGroupLabels":["Dose Escalation","Dose Expansion"],"otherNames":["OP-1250"]},{"type":"DRUG","name":"Palbociclib","description":"Palbociclib is an approved CDK 4/6 Inhibitor drug","armGroupLabels":["Dose Escalation","Dose Expansion"],"otherNames":["Ibrance®️"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incidence of Dose Limiting Toxicities","timeFrame":"From Cycle 1 Day 1 through C1 Day 28"},{"measure":"Characterization and Incidence in Adverse Events and Serious Adverse Events","timeFrame":"From initial inform consent date through 30 days post last dose"},{"measure":"Plasma levels of OP-1250 and Palbociclib","timeFrame":"Up to 9 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Confirmed and evaluable locally advanced or metastatic breast cancer\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Must not have received prior oral endocrine or targeted therapy ≤ 2 weeks prior to first dose\n* Must not have received prior chemotherapy, antibody therapy, or investigational therapy ≤ 4 weeks prior to the first dose\n* Prior radiotherapy must have been completed 2 weeks prior to first dose\n* Adequate safety laboratory tests\n* Willingness to use effective contraception\n\nExclusion Criteria:\n\n* Gastrointestinal disease\n* Significant hepatic disease\n* Significant cardiovascular disease\n* Significant ECG abnormalities\n* History of pulmonary embolism or high risk of thrombosis\n* Known HIV infection\n* Active infection (requiring antimicrobial therapy)\n* Pregnant","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Sue Johnson","affiliation":"Olema Pharmaceuticals, Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Clinical Trial Site","city":"Waratah","state":"New South Wales","zip":"2298","country":"Australia","geoPoint":{"lat":-32.90667,"lon":151.72647}},{"facility":"Clinical Trial Site","city":"Westmead","state":"New South Wales","zip":"2145","country":"Australia","geoPoint":{"lat":-33.80383,"lon":150.98768}},{"facility":"Clinical Trial Site","city":"South Brisbane","state":"Queensland","zip":"4101","country":"Australia","geoPoint":{"lat":-27.48034,"lon":153.02049}},{"facility":"Clinical Trial Site","city":"Southport","state":"Queensland","zip":"4215","country":"Australia","geoPoint":{"lat":-27.96724,"lon":153.39796}},{"facility":"Clinical Trial Site","city":"Clayton","state":"Victoria","zip":"3168","country":"Australia","geoPoint":{"lat":-37.91667,"lon":145.11667}},{"facility":"Clinical Trial Site","city":"Frankston","state":"Victoria","zip":"3199","country":"Australia","geoPoint":{"lat":-38.14458,"lon":145.12291}},{"facility":"Clinical Trial Site","city":"Geelong","state":"Victoria","zip":"3220","country":"Australia","geoPoint":{"lat":-38.14711,"lon":144.36069}},{"facility":"Clinical Trial Site","city":"Nedlands","state":"Western Australia","zip":"6009","country":"Australia","geoPoint":{"lat":-31.98184,"lon":115.8073}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D001943","term":"Breast Neoplasms"}],"ancestors":[{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D001941","term":"Breast Diseases"},{"id":"D012871","term":"Skin Diseases"},{"id":"D017437","term":"Skin and Connective Tissue Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C500026","term":"palbociclib"}]}},"hasResults":false}